We expect that ANAVEX’s lead drug candidate ANAVEX 2-73 -targeting Alzheimer’s disease- will enter first human clinical trials in early 2010. ANAVEX has completed most preclinical testing on ANAVEX 2-73 (Alzheimer’s disease) and is currently preparing the Investigational New Drug (IND) file. In parallel, Anavex is preparing the IND file for one other CNS drug targeting epilepsy and one IND file for an oncology drug that could directly enter Phase II clinical trial.

Other early-stage preclinical research (see diagram) involves drug candidates that target diseases like diabetes, depression, neuropathic pain and various types of cancer.

The company has over 30 novel drug candidates and is open to discussions with industrial partners.